The precision oncology platform is based on research by Duke and Hubrecht Institute faculty and the cash will fund technology development and clinical studies.

Xilis, a US-based cancer analysis technology developer based on research at Duke University and Hubrecht Institute, completed a $70m series A round yesterday backed by Duke’s endowment.
The round was led by Abu Dhabi state-owned Mubadala Capital, and also featured Duke Angel Network as well as GV, a corporate venture capital subsidiary of conglomerate Alphabet.
LSP, Catalio Capital Management, Felicis Ventures, Two Sigma Ventures, Pear VC, KdT Ventures and Alix Ventures filled out the investor line-up.
Founded…